NMDA receptors are involved in neurodevelopmental processes such as synaptogenesis, learning, and memory. Structurally, NMDA receptors are composed of 2 subunits of GluN1 and GluN2, which are specifically encoded by the *GRIN1* and *GRIN2A* to *GRIN2D* genes, respectively.^[@R1]^ While single nucleotide and copy number variants (CNVs) in the NMDA receptor subunits *GRIN1*, *GRIN2A*, and *GRIN2B* have been associated with a range of neurodevelopmental disorders (NDDs), little is known about the association of *GRIN2D* variants and NDDs. Recently, de novo missense mutations in *GRIN2D* (p.Val667Ile) have been identified as the cause of severe epileptic encephalopathy^[@R2]^ in 2 independent patients. However, whether CNVs covering the *GRIN2D* locus are also associated with disease has not been studied. *GRIN2D* is encoded at the end of the long arm of chromosome 19 at the 19q13.33 locus. We hypothesize that dosage changes in *GRIN2D* are highly likely to be disease associated based on the high sequence homology, expression during neurodevelopment, and a functional relationship with the established disease-associated paralogous genes.

Methods {#s1}
=======

Standard protocol approvals, registrations, and patient consents {#s1-1}
----------------------------------------------------------------

We obtained approval from an ethical standards committee on human experimentation (institutional or regional) for any experiments using human subjects. Written informed consent was obtained from all patients (or guardians of patients) participating in the study (consent for research), following the guidelines provided by ClinVar and DECHIPER databases. We obtained authorization for disclosure (consent to disclose) of the photograph that may be published in the journal, in derivative works by the AAN, or on the journal\'s website.

Data analysis {#s1-2}
-------------

Using the gene-oriented query "*GRIN2D*," we accessed 2 publicly available repositories of clinical genetic variation: (1) The Database of Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources, DECIPHER^[@R3]^ (URL: <https://decipher.sanger.ac.uk>, accessed on July 2016) and (2) The public archive of interpretations of clinically relevant variants, ClinVar^[@R4]^ (URL: <http://www.ncbi.nlm.nih.gov/clinvar>, accessed on July 2016). For DECIPHER patients, the individual scientists were contacted to acquire further phenotype information including the presence of intellectual disability (ID), developmental delay (DD), seizures, hypotonia, dysmorphism (Dysm), learning difficulties, behavioral problems as well as social communication, and behavioral disorders of the autism spectrum disorder.^[@R5]^ We considered only DECIPHER entries with positive submitter contact. All phenotypes evaluated were considered as binary denominators (i.e., Yes/No). Gene annotations of the extracted CNVs refer to the genome build GRCh37/hg19. A consensus region was determined with an in-house Python script (available on request). Genes inside the consensus region were further evaluated as disease candidate genes with additional publicly available resources for (1) brain expression, strongly brain-expressed genes (n = 4,756), specified by a log (RPKM) \>4.5 of the BrainSpan RNA.Seq transcriptome data set^[@R6]^; (2) overlapping CNVs reported in the curated control inclusive map of the Database of Genomic Variants^[@R7]^; (3) loss-of-function (LoF) intolerance reported in the Exome Aggregation Consortium,^[@R8]^ given by a probability of being LoF intolerant (pLI score) equal to or greater than 0.9 based on the observed genetic variation of 60,706 healthy individuals; and (4) overlapping CNVs reported in 20,227 controls.^[@R9]^ Genome-wide brain-specific noncoding functional elements were extracted from the GenoSkyline; project (<http://genocanyon.med.yale.edu/GenoSkyline>), which implements a statistical framework based on high-throughput genetic and epigenetic data to predict tissue-specific functional noncoding elements.^[@R10]^

Results {#s2}
=======

We detected 11 patients with CNVs overlapping the 19q13.33 locus ([table 1](#T1){ref-type="table"}). Of interest, all of them were duplications. Three were annotated in ClinVar (patients 1 through 3) and 8 in DECIPHER (patients 4 through 11). Although a ninth individual did fulfill the inclusion criteria (DECIPHER entry 275388), given the actual size of the reported variant in comparison with the entire chromosome 19 (CNV = 58.83 Mb vs Chr19 = 59.12 Mb), it was considered a chromosome trisomy and therefore was excluded. Detailed clinical phenotypes are provided in [table 1](#T1){ref-type="table"}. Notably, all patients were reported to have mild to severe forms of NDDs. Of all the phenotypes evaluated, mild but distinct dysmorphic features were the most frequent (n = 8), followed by seizures (n = 6, including generalized tonic and febrile seizures), ID (n = 5), and DD (n = 4). In particular, dysmorphisms were present in patients carrying CNVs larger than 3 Mb (pathogenic size according to the American College of Human Genetics). The image of 1 of such patients is shown in [figure, A](#F1){ref-type="fig"}, showing a child with signs of macrostomia, mid-face hypoplasia, and progenia.

###### 

Clinical phenotypes of the 11 retrieved patients with GRIN2D variants at the 19q13.33 locus
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![Genomic and facial overview of the microduplications overlapping the GRIN2D gene found in the retrieved patients\
(A) Clinical anteroposterior facial photograph of patient 10 depicting characteristic facial features. (B) Thirteen patients were identified with GRIN2D duplications at the 19q13.33 locus. Blue horizontal bars represent the respective microduplication size and breakpoints according to GRCh37/hg19 human genome reference in a 12-Mb genomic window. Gray horizontal bars represent the respective microduplication reported in the study by Dorn et al.^[@R13]^ Carvalheira et al.^[@R11]^ and Wang et al.^[@R12]^ in which no exact copy number variant boundaries are specified (\*). Microduplications larger than the depicted genomic interval are shown with arrows at boundaries (patients 1, 2, 7, and 8). Bottom panel: The consensus duplicated region of the 12 patients is depicted in the blue horizontal bar in a 405-kb window. Thirteen RefSeq genes are located in this region.](NG2017006510FF1){#F1}

For DECIPHER entries with available parental information, 85.7% (n = 6) of observed microduplications were de novo, and only 1 was inherited from an affected family member. The majority of (87.5%, n = 7) patients did not carry additional CNVs, and none of the additional CNVs found in 3 patients covered a known disease locus or known disease genes. All 11 CNVs were highly heterogeneous in their size (average = 4.99 Mb; SD = 4.05 Mb) and breakpoint distribution (encompassing from Chr19: 45.38 Mb--59.09 Mb, Hg19) ([table 1](#T1){ref-type="table"}).

To identify additional CNVs absent in ClinVar and/or DECIPHER databases, we screened the literature and retrieved 3 additional studies, including 6 patients with duplications at the 19q13.33 locus.^[@R11][@R12][@R13]^ All of these patients had seizures. Three patients carried CNVs of 1.22 Mb size, whereas the remaining 3 duplications were \>10 Mb. Patients affected by the large CNVs were, in addition to seizures, also affected by other NDDs including ID and dysmorphism.

Of interest, the 2 independent patients with the p.Val667Ile mutation on *GRIN2D* featured similar NDDs including DD, dysmorphism, seizures, and muscular hypotonia ([table 1](#T1){ref-type="table"}).

Overall, the consensus duplicated region was determined to be located within the coordinates 48,520,809 bp--48,926,006 bp, with a final size of 405 kb. This is consistent with previous reports.^[@R11][@R12][@R13]^ The consensus region overlapped 13 RefSeq genes ([figure, B](#F1){ref-type="fig"}) that were further examined for brain expression, the presence of CNVs overlapping these genes in control cohorts, and variation intolerance ([table 2](#T2){ref-type="table"}). Four genes persisted above all available filters, namely, the caspase recruitment domain family member 8 (*CARD8*), the chromosome 19 open reading frame 68 (*C19orf68*), the KDEL endoplasmic reticulum protein retention receptor 1 (*KDELR1*), and the glutamate ionotropic receptor NMDA type subunit 2D (*GRIN2D*). In our view, these 4 genes represent the most promising candidates.

###### 

Consensus region gene annotation and candidate gene filtering
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We also searched for noncoding brain-specific functional elements within the consensus region. A total of 291 were found overlapping 9.87% of the consensus region (40,019 bp). Within the consensus regions of the duplications, the density of noncoding elements was not significantly higher than that outside of chromosome 19.

Discussion {#s3}
==========

Here, we report on 11 patients with duplications at a potential novel disease locus within 19q13.33. Several lines of evidence support the hypothesis that duplications at this locus are associated with NDDs: (1) duplications at this locus are virtually absent in healthy individuals from the general population^[@R8]^; (2) all of the identified duplications with parental information arose de novo with the exception of patient 4, which according to DECIPHER was inherited from an affected parent with a similar phenotype (DECIPHER entry 257554); (3) none of the patients carried additional likely pathogenic CNVs; and (4) all duplications covered multiple plausible disease candidate genes.

The NDDs observed in the 11 patients were characterized by dysmorphism as the most prominent feature, followed by ID and seizures ([table 1](#T1){ref-type="table"}). Our observations are in agreement with previous reports.^[@R11][@R12][@R13]^ Although, 1 example^[@R12]^ focused exclusively on seizures, we cannot rule out that other NDDs were actually present in those patients. Similarly, we acknowledge that DD, behavioral problems, and learning difficulties may be subject to interobserver variability to some extent. In this regard, future clinical studies of 19q13.33 duplication carriers need to be conducted to draw detailed and robust genotype-phenotype conclusions. Since previous reports from the literature were based on low-resolution cytogenetic methods,^[@R13]^ identification of the underlying disease gene was not possible. Here, we show that by integration of multiple CNVs data sets from public repositories, we are able to narrow down the disease-associated genomic sequence to a few candidate genes at the 19q13.33 locus ([figure](#F1){ref-type="fig"}).

Our included data sets do not allow estimation of 19q13.33 duplication frequency. However, the absence of 19q13.33 duplications in CNVs databases of the general population and the presence of only a few variant carrying patients in diagnostic CNVs databases with heterogeneous breakpoints indicate that 19q13.33 duplications are extremely rare ([table 2](#T2){ref-type="table"}).

All 11 of the identified patient CNVs shared a genomic interval of 405 kb, which includes 4 genes with genetic, population and biological support of disease association. These included *CARD8*, *C19orf68*, *KDELR1*, and *GRIN2D*. For *CARD8*, *C19orf68*, and *KDELR1*, no association with NDDs has been reported in the literature to date. Although we cannot rule out that brain-specific noncoding elements at 19q13.33 could be involved in the development of NDDs, *GRIN2D* represents a plausible candidate gene for association with NDDs. *GRIN2D*, encoding the NMDA receptor subunit GluN2D, is highly expressed prenatally and after birth before progressively declining through adulthood.^[@R14]^ It is possible that *GRIN2D* microduplications may predispose to disease susceptibility in a dose-dependent manner by enhancing GluN2D expression during development, thereby influencing the NMDA receptor composition, which might provoke changes in neuronal networks, thus contributing to hyperexcitability and neurologic diseases.^[@R15]^ Besides CNVs, the *GRIN2D* gene is also depleted due to negative selection of missense and truncating variants in the general population, supporting the *GRIN2D* association with disease.^[@R8]^ In agreement, 2 recently identified *GRIN2D* single nucleotide variants also lead functionally to a gain-of-function mutation in 2 patients with similar outcomes^[@R2]^ ([table 1](#T1){ref-type="table"}). Beyond the potential diagnostic relevance, our identification of *GRIN2D* as a possible new NDD gene has a potential clinical application, since memantine, a low-affinity therapeutic NMDA channel blocker, selectively blocks extrasynaptic NMDA receptors that are likely to contain GluN2C/2D subunits.^[@R16]^ This might especially be relevant for patients with gain-of-function mutations or microduplications.^[@R2]^
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